A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer

This study has been completed.

Study NCT00001446 Information provided by National Institutes of Health Clinical Center (CC)

First Received: November 3, 1999 Last Updated: March 3, 2008 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	July 2001
Estimated Primary Completion Date:	No date given

No publications provided by National Institutes of Health Clinical Center (CC)

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Sissung TM, Danesi R, Kirkland CT, Baum CE, Ockers SB, Stein EV, Venzon D, Price DK, Figg WD. Estrogen receptor ? and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy. J Clin Endocrinol Metab. 2011 Feb;96(2):E368-72. Epub 2010 Nov 24.